BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Viskase Holdings, Inc. ENZN
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.07
Dividend / sh · FY25
—
Payout · FY25
-37%
ROE · FY25
-1411.6%
Net margin · FY25
—
Dividend coverage
-0.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -0.07
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-1411.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-7.6%
Each USD of equity lost 1412 cents this year.
Returned to shareholders
USD 1.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.3M
Net buybacks—
Share of profit-37.4%
Consecutive raises—
USD 1.3M in dividends went back to shareholders in a year without profit.
Growth
−34.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−66.7%
−34.0%
−50.8%
−39.7%
Dividend / share
−58.2%
−40.4%
Returned to shareholders
−28.7%
−15.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+0.0%
Change, 10 years—
The share count grew 0% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 42.8M
total assets, end of FY2025
Total assetsUSD 42.8M
EquityUSD -2.5M
CashUSD 42.6M
Current ratio58.57×
Equity funds -6% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.1
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.1
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
−0.0
0.0
·
Income tax $B
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
Net income $B
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.2
0.0
EPS, diluted $
−0.07
0.01
0.00
−0.02
−0.03
−0.03
−0.02
0.13
0.12
−0.03
0.49
0.65
0.38
−0.06
−0.40
3.03
0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
0.15
0.85
0.00
2.05
2.00
2.00
0.00
·
Payout %
−37
164
93
·
−0
−0
−813
0
122
−589
174
15
495
−3139
−0
·
·
ROE %
−1411.6
·
·
−4.5
−7.7
−19.5
−9.3
48.5
55.9
−7.9
90.7
165.2
43.9
−2.0
−7.8
92.0
1.3
Shares out B
0.07
0.07
0.07
0.07
0.07
0.07
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.05
0.06
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed